Clinical Trials on Alzheimer's Disease Conference (CTAD) 2024

CTAD is a conference entirely focused on therapeutic trials in Alzheimer’s disease, featuring leaders in the Alzheimer’s field from both research and academia with the aim of progressing effective treatments.

Conference Content

News Nuggets

CTAD – News Nugget 1 – A change to donanemab dosing could reduce ARIA-E rates

CTAD – News Nugget 2 – Experts make recommendations on real-world donanemab use

CTAD – News Nugget 3 – Real-world evidence supports ‘on label’ lecanemab use for patients with AD

CTAD – News Nugget 4 – Discordant CSF/PET amyloid-β result signals need for follow-up before treatment

CTAD – News Nugget 5 – Off-target vascular amyloid binding may not explain differences in ARIA-E rates

Breakfast Bites - Video

CTAD – Breakfast Bite 8

CTAD – Breakfast Bite 9

Breakfast Bites - Podcast

CTAD – Breakfast Bite 8 – Podcast

CTAD – Breakfast Bite 9 – Podcast

Expert Panel Discussion & Accreditation

Experts in conversation: highlights from CTAD 1 – Baseline Activity Questions

CTAD – Experts in Conversation 1 – Enhancing safety and efficacy in amyloid-targeted therapies

Experts in conversation: highlights from CTAD 1 – Post Activity Questions

Experts in Conversation: highlights from CTAD 1 – Feedback and claim CME 1 Activity

Expand

Activity Content

CTAD – Experts in Discussion 1 – CME Credit

Experts in conversation: highlights from CTAD 2 – Baseline Activity Questions

CTAD – Experts in Conversation 2 – Representation in clinical trials and implementation of blood-based biomarkers

Experts in conversation: highlights from CTAD 2 – Post Activity Questions

Experts in Conversation: highlights from CTAD 2 – Feedback and claim CME 1 Activity

Expand

Activity Content

CTAD – Experts in Discussion 2 – CME Credit

CTAD – Slide Deck

Microdigest

CTAD – Microdigest 3

Test Your Knowledge

CTAD – Pop Quiz

Conference Content

Like this content?